SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Pharmaceutical

SciClone Pharmaceuticals Inc

宏 赵

David Wilgus

Peter Shao

Li Mao

岩松（Phil） 常

Cecile Pan

Bokang Zhou

The Business Development and Strategy team at SciClone Pharmaceuticals Inc is responsible for identifying growth opportunities, forming strategic partnerships, and developing plans to expand the company's footprint in the pharmaceutical market, particularly in China. They analyze market trends, assess competitive landscapes, and evaluate potential collaborations to drive the company's product portfolio, including ZADAXIN and other therapies, ensuring alignment with corporate goals and maximizing stakeholder value.

Business Development and Strategy

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

About

Team members

Other teams at SciClone Pharmaceuticals Inc

Leadership Team

Medical Affairs and Regulatory Compliance